金城醫藥(300233.SZ):回購價上限由24元/股調整為23.8元/股
格隆匯5月26日丨金城醫藥(300233.SZ)公佈,鑑於公司2019年年度權益分派已實施完畢,公司對此次回購股份的價格上限進行調整,此次回購價格上限由24元/股調整為23.8元/股。
因此次回購資金總額不低於人民幣6000萬元,不超過人民幣12000萬元,在回購股份價格調整為不超過23.8元/股的條件下,按回購金額上限測算,預計回購股份數量為504.2016萬股,佔公司總股本的1.28%;按回購金額下限測算,預計回購股份數量約為252.1008萬股,佔公司總股本的0.64%。具體回購數量以回購期限屆滿時實際回購的股份數量為準。回購股份的實施期限為自股東大會審議通過回購股份方案之日起12個月內。其他內容保持不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.